Date: Tuesday, January 8th, 2019
Source: Wall Street Journal (https://www.wsj.com)
Summary: A Boston-area biotech says it may have a found a way to bring off the expected seven-figure cost of its experimental gene therapy: paying on installment. Bluebird Bio is developing plans to sell its first gene-replacement therapy, for a rare inherited blood disease, on a five-year installment plan, with each annual payment contingent on its treatment’s continued effectiveness.
Full article address: https://www.wsj.com/articles/biotech-proposes-paying-for-pricey-drugs-by-installment-11546952520